Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
08 mars 2022 06h30 HE
|
Matinas BioPharma Holdings, Inc.
– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 – – Potential Pathway to NDA Submission for MAT2203 with Confirmatory Data...
Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial and Operational Results on March 8, 2022
28 févr. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of...
Matinas BioPharma Provides Business Update and 2022 Strategic Outlook
25 janv. 2022 06h30 HE
|
Matinas BioPharma Holdings, Inc.
– End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial – – Cohort 4 of...
Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022
18 janv. 2022 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of...
Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
16 déc. 2021 06h30 HE
|
Matinas BioPharma Holdings, Inc.
– DSMB evaluated both safety and efficacy data in recommending cohort progression – – Data from third patient cohort confirm antifungal activity above pre-defined threshold target for success, while...
Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer
06 déc. 2021 06h30 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Conference
18 nov. 2021 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights
08 nov. 2021 06h35 HE
|
Matinas BioPharma Holdings, Inc.
– Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously...
Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2021 Financial and Operational Results on November 8, 2021
02 nov. 2021 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma Selected to Participate in the B. Riley Fall 2021 Growth Biotech Best Ideas Series
25 oct. 2021 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...